Heartflow, Inc. Common Stock
HTFL
$50.75
+2.38%
Heartflow, Inc. is a commercial-stage medical technology company that develops software and artificial intelligence designed to provide non-invasive diagnosis and management of coronary artery disease, with a product portfolio spanning Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis. Operating as a single reportable segment in non-invasive coronary artery disease detection, the company derives the majority of its revenue from the United States, with a secondary presence in Europe, positioning it as a focused AI-driven challenger to traditional invasive diagnostic pathways such as catheter-based angiography. The current investor narrative centers on the company's August 2026 second-quarter results, which featured raised full-year guidance and were described by commentators as signaling accelerating growth and improving profitability, driving a sharp re-rating in the shares. At the same time, the stock remains a high-multiple, still-unprofitable story with a small employee base of 843, so the debate is whether the recent growth inflection is durable enough to justify the valuation and eventually deliver consistent GAAP profitability.…
HTFL
Heartflow, Inc. Common Stock
$50.75
Investment Opinion: Should I buy HTFL Today?
Based on the synthesis of technical, fundamental, and analyst data, the appropriate rating for HTFL is Hold. The core thesis is that Heartflow possesses a differentiated AI-driven diagnostic platform with a software-like gross margin of 76.80% and a fortress balance sheet (current ratio 5.20, debt-to-equity 0.073), but the stock's 14.12x price-to-sales multiple and 19.69x EV/Sales already price in substantial growth, and the average analyst target of $44.78 implies 11.8% downside from the current price of $50.75. The consensus recommendation is buy (mean 1.6), yet the stock trades above the average target, suggesting the easy money has been made in the near term.
Supporting evidence for a Hold includes the strong post-earnings momentum (up 95.04% over six months), the raised guidance that drove a 35.7% single-day gain, and the tight analyst EPS and revenue estimate ranges, which indicate confidence in the near-term trajectory. However, the company remains unprofitable with a net margin of -66.35% and negative operating cash flow (price-to-cash-flow -46.02), and the forward EPS of $0.613 represents a dramatic swing from trailing EPS of -$0.047. The PEG ratio of 2.03 suggests the stock is not cheap even on growth-adjusted terms, and the wide analyst target range ($39 to $55) highlights uncertainty.
The biggest risks that could invalidate the Hold rating include a deceleration in revenue growth below 20% year-over-year, a delay in the profitability inflection beyond 2027, or a competitive or reimbursement setback. The rating would upgrade to Buy if the stock pulls back to the $40-$42 range (near the analyst average target) while maintaining growth momentum, or if forward EPS estimates are revised upward. Conversely, a downgrade to Sell would be warranted if revenue growth slows below 15% or if the company signals a need for additional equity financing. Relative to its own brief history and sector peers, HTFL appears overvalued at current levels, but the premium may be justified if the growth inflection proves durable.
Sign up to view all
HTFL 12-Month Price Forecast
Heartflow presents a compelling growth story with a differentiated AI platform and a recent inflection in revenue, but the stock's extreme valuation and lack of profitability create a balanced risk/reward at current levels. The 25% bull, 50% base, and 25% bear probability distribution reflects the uncertainty around the durability of the growth inflection and the path to profitability. The base case assumes the company meets consensus estimates, leading to a modest pullback toward the analyst average target. I would upgrade to bullish if the stock pulls back to the $42-$45 range while maintaining growth momentum, or if forward EPS estimates are revised significantly higher. I would downgrade to bearish if revenue growth decelerates below 20% or if the company signals a need for additional equity financing.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Heartflow, Inc. Common Stock's 12-month outlook, with a consensus price target around $44.78 and implied upside of -11.8% versus the current price.
Average Target
$44.78
0 analysts
Implied Upside
-11.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$39 - $55
Analyst target range
Heartflow is covered by 9 analysts, and the consensus recommendation is "buy" with a recommendation mean of 1.6 on a scale where 1.0 is a strong buy and 5.0 is a strong sell, indicating a clearly bullish tilt. The average price target is $44.78, which implies approximately -11.8% downside from the current price of $50.75, a notable disconnect given that the stock has already blown through the consensus target. The consensus forward EPS estimate of $0.613 (range $0.598 to $0.631) and revenue estimate of $515.9 million (range $506.2 million to $527.4 million) show tight dispersion, suggesting analysts broadly agree on the near-term financial trajectory even if their price targets have not kept pace with the stock's rally.
The full target range spans $39.00 at the low end to $55.00 at the high end, a spread of roughly 41% around the average, which signals meaningful uncertainty about the appropriate multiple for this still-unprofitable, recently listed company. The high target of $55.00 implies about 8.4% upside and likely assumes continued guidance beats, accelerating FFRCT and Plaque Analysis adoption, and a credible path to the $0.61 forward EPS, while the low target of $39.00 implies roughly 23% downside and likely prices in slower hospital adoption, competitive pressure from alternative diagnostic modalities, or a delay in the profitability inflection. The fact that the average target sits below the current price suggests analysts have been slow to revise upward after the August earnings gap, and the stock trading above consensus could be read either as momentum running ahead of fundamentals or as a sign that estimates and targets are due for further upward revisions. With no institutional ratings history provided, it is not possible to determine whether analysts have been recently upgrading or downgrading, but the wide target spread and the stock's position above the average target argue for caution on chasing the rally at current levels.
Drowning in data?
Find the real signal!
Bulls vs Bears: HTFL Investment Factors
The bull case rests on a powerful post-earnings re-rating, a software-like gross margin of 76.80%, a fortress balance sheet with a current ratio of 5.20, and a differentiated AI diagnostic platform that is gaining commercial traction. The bear case centers on an extreme valuation (14.12x sales, 19.69x EV/Sales), deep unprofitability (net margin -66.35%), negative cash flow, and a stock trading 11.8% above the average analyst target of $44.78. Currently, the bear evidence on valuation and profitability is more concrete, while the bull case relies on extrapolating the recent growth inflection. The single most important tension is whether the Q2-driven acceleration in revenue and raised guidance can translate into the $0.613 forward EPS that analysts expect; if it does, the premium multiple is justified, but if adoption slows, the stock could quickly revert toward its pre-earnings range.
Bullish
- Explosive post-earnings momentum: HTFL gapped from $31.01 to $42.08 on August 14, 2026, a single-session move of roughly 35.7% after Q2 results and raised guidance. The stock has since consolidated and closed at a fresh high of $50.75, up 95.04% over six months and 75.18% year-to-date, indicating the market is rewarding the growth inflection.
- Software-like gross margin: Gross margin stands at 76.80%, far above typical medtech device peers, reflecting the high incremental profitability of Heartflow's AI-driven software platform. This margin structure provides substantial operating leverage if revenue scales as analysts expect.
- Fortress balance sheet: The current ratio of 5.20 and debt-to-equity of just 0.073 mean Heartflow has ample liquidity and virtually no leverage. This gives the company runway to fund its path to profitability without near-term refinancing risk.
- Analyst consensus buy with tight estimates: Nine analysts rate the stock a buy with a recommendation mean of 1.6, and forward EPS estimates are tightly clustered between $0.598 and $0.631. Revenue estimates of $515.9 million (range $506.2M to $527.4M) also show high agreement, suggesting a credible near-term trajectory.
Bearish
- Trading above consensus target: The average analyst price target is $44.78, implying roughly 11.8% downside from the current price of $50.75. The stock has blown through the consensus target, which historically signals either momentum running ahead of fundamentals or impending analyst upgrades that have yet to materialize.
- Extreme valuation multiples: At 14.12x price-to-sales and 19.69x EV/Sales, HTFL trades at a steep premium to medtech and healthcare IT peers that typically command mid-to-high single-digit sales multiples. The PEG ratio of 2.03 indicates the stock is not cheap even after adjusting for growth.
- Deeply unprofitable with negative cash flow: Net margin is -66.35%, operating margin is -36.39%, and price-to-cash-flow is -46.02. Despite the 76.80% gross margin, operating expenses still far exceed gross profit, and the company is burning cash, with ROE of -38.85% and ROA of -18.06%.
- High volatility and drawdown risk: The stock experienced a max drawdown of -48.66% in the past year and a 35.7% single-day earnings gap. Trading just 2.8% below its 52-week high of $52.22, it is vulnerable to profit-taking on any disappointment, and the wide analyst target range ($39 to $55) signals uncertainty.
HTFL Technical Analysis
Heartflow is in a powerful, sustained uptrend that has accelerated dramatically over the past six months. The stock is up 56.25% over the trailing year, 95.04% over six months, and 75.18% year-to-date, and at a current price of $50.75 it sits roughly 97.2% of the way through its 52-week range of $20.13 to $52.22. That positioning near the top of the annual range signals strong momentum but also leaves little margin for error, as the stock is trading just 2.8% below its 52-week high and is vulnerable to profit-taking on any disappointment. The magnitude of the move, including a max drawdown of -48.66% at some point in the past year, confirms this is a high-volatility name where trend-following has been rewarded but drawdown risk is real.
Short-term momentum is strongly positive and broadly consistent with the longer-term trend, though the pace has cooled from its August surge. The stock is up 11.47% over the past month and 50.86% over three months, with the one-month gain outpacing the S&P 500's -0.96% return by 12.43 percentage points of relative strength. The most striking feature of the price history is the gap from $31.01 on August 13 to $42.08 on August 14, a single-session move of roughly 35.7% that coincided with the Q2 earnings release and raised guidance. Since then the stock has consolidated in a $45 to $50 range, and the most recent close of $50.75 is a fresh high, suggesting the post-earnings consolidation is resolving to the upside rather than fading.
Key technical levels are well defined by the recent trading structure. Immediate resistance sits at the 52-week high of $52.22, and a decisive breakout above that level would confirm the uptrend and likely invite momentum-driven inflows; support is layered at the $45 to $46 area (the September pullback low near $45.49) and then the $42 gap-fill zone from the August earnings move, with the 52-week low of $20.13 as the ultimate backstop. Beta is not available in the provided data, but the 48.66% max drawdown and the 35.7% single-day earnings gap make clear this is a high-beta, event-driven stock that warrants smaller position sizing and wider stops than a diversified healthcare index. Volume of 6.61 million shares on the latest session indicates active participation, and the short ratio of 2.93 suggests short interest is moderate rather than a crowded squeeze setup.
Beta
—
—
Max Drawdown
-48.7%
Largest decline past year
52-Week Range
$20-$52
Price range past year
Annual Return
+56.3%
Cumulative gain past year
| Period | HTFL Return | S&P 500 |
|---|---|---|
| 1m | +11.5% | -0.5% |
| 3m | +50.9% | +2.3% |
| 6m | +95.0% | +16.6% |
| 1y | +56.3% | +14.8% |
| ytd | +75.2% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HTFL Fundamental Analysis
Heartflow's growth trajectory appears to be inflecting sharply upward, though the provided dataset does not include quarterly financial statements or revenue segment detail. The most concrete evidence is the August 14, 2026 news item reporting strong Q2 results and raised guidance, which triggered a 35.7% single-day move, and the analyst consensus revenue estimate of approximately $515.9 million (range $506.2 million to $527.4 million) for the forward period. The company's market capitalization of roughly $2.49 billion against that revenue estimate implies the business is still relatively early in scaling its commercial footprint, and the fact that guidance was raised rather than merely maintained suggests management sees broadening adoption of its FFRCT, Roadmap, and Plaque products. With only 843 employees and a single reportable segment, operating leverage on incremental revenue could be substantial if the growth rate holds.
Profitability remains the central fundamental question, as the company is not yet generating positive earnings. The trailing EPS is -$0.047, net margin is -66.35%, and operating margin is -36.39%, indicating that operating expenses still substantially exceed gross profit despite a healthy gross margin of 76.80%. That gross margin is characteristic of a software and AI-driven medtech model with high incremental margins, and the gap between the 76.80% gross margin and the -36.39% operating margin quantifies how much the company is currently spending on sales, marketing, and R&D to build its market. The forward EPS estimate of $0.613 versus trailing EPS of -$0.047 implies the analyst community expects a dramatic swing to profitability, which is the crux of the bull case and the key risk if adoption slows.
Balance sheet and cash flow metrics paint a mixed but generally low-leverage picture. The debt-to-equity ratio is just 0.073, indicating minimal financial leverage, and the current ratio of 5.20 reflects very strong short-term liquidity, meaning the company has ample runway to fund operations without near-term refinancing risk. However, the price-to-cash-flow ratio of -46.02 and the negative ROE of -38.85% and ROA of -18.06% confirm that the business is currently burning cash and generating negative returns on capital. The combination of a fortress-like current ratio and negative cash flow suggests the company is funding its growth from its balance sheet rather than from internally generated cash, which is acceptable at this stage but means future equity dilution or a path to cash-flow breakeven will be critical milestones for investors to monitor.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HTFL Overvalued?
Because Heartflow's trailing net income is negative (EPS of -$0.047, net margin of -66.35%), the PE ratio is not a meaningful primary metric; the trailing PE of -21.28 and forward PE of -197.24 are artifacts of near-zero or negative earnings and should be disregarded. The appropriate lead metric is the price-to-sales ratio, which stands at 14.12x, with an EV/Sales multiple of 19.69x. The forward EPS estimate of $0.613 implies the market expects a rapid swing to profitability, and the enormous gap between the negative trailing PE and the positive forward EPS estimate reflects the market pricing in a near-term earnings inflection rather than current fundamentals.
Relative to the broader healthcare information services and medical technology sector, a 14.12x price-to-sales multiple is a clear premium, as most established medtech and healthcare IT peers trade in the mid-single-digit to high-single-digit sales multiple range. The premium is partly justified by the 76.80% gross margin, which is software-like rather than device-like, and by the company's AI-driven, non-invasive diagnostic positioning, which offers a differentiated value proposition versus invasive alternatives. However, with a net margin of -66.35% and an operating margin of -36.39%, the company is far less profitable than the typical peer commanding a premium multiple, so the valuation is effectively a bet on future margin expansion rather than current earnings power. The PEG ratio of 2.03 suggests that even on growth-adjusted terms, the stock is not cheap.
Historical valuation context is limited because the provided historical ratios dataset is empty, and the company only listed on August 8, 2025, giving it roughly 13 months of public trading history. What can be inferred from the price data is that the stock has re-rated dramatically: it traded in the $24 to $35 range from March through early August 2026 before gapping to the $42 to $50 range after Q2 earnings, meaning the current sales multiple is near the high end of its short public history. The price-to-book ratio of 8.27x is also elevated, reflecting a relatively thin book value against a $2.49 billion market cap. Investors are therefore paying a premium to both the sector and the stock's own brief trading history, which leaves the shares sensitive to any deceleration in growth or delay in the path to profitability.
PE
-21.3x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-26.5x
Enterprise Value Multiple
Investment Risk Disclosure
Heartflow's financial risk profile is dominated by its lack of profitability and negative cash flow. Despite a healthy 76.80% gross margin, the company reported a net margin of -66.35% and an operating margin of -36.39%, meaning operating expenses are consuming far more than gross profit. The price-to-cash-flow ratio of -46.02 and negative ROE of -38.85% confirm that the business is burning cash, and with a forward EPS estimate of $0.613, any delay in the profitability inflection could force additional equity dilution or a sharp re-rating. The debt-to-equity ratio of 0.073 and current ratio of 5.20 provide a liquidity cushion, but the company remains dependent on external capital to fund growth until it reaches cash-flow breakeven.
Market and competitive risks are elevated given the stock's extreme valuation and recent price action. At 14.12x trailing sales and 19.69x EV/Sales, HTFL trades at a significant premium to medtech and healthcare IT peers, leaving it vulnerable to multiple compression if growth decelerates or if interest rates remain elevated. The stock has a beta that is not provided, but the 48.66% max drawdown and 35.7% single-day earnings gap indicate high volatility and event-driven risk. Competitive threats from alternative diagnostic modalities, including traditional invasive angiography and other non-invasive imaging technologies, could pressure adoption of Heartflow's FFRCT and Plaque Analysis products. Additionally, the company's revenue is concentrated in the United States, exposing it to changes in reimbursement policies and hospital capital spending cycles.
The worst-case scenario would involve a combination of slowing revenue growth, delayed profitability, and multiple compression. If Q3 or Q4 results show decelerating adoption or if guidance is lowered, the stock could retrace toward its pre-earnings level of $31 or even its 52-week low of $20.13. From the current price of $50.75, a decline to the 52-week low would represent a loss of approximately 60%, while a drop to the analyst low target of $39.00 would imply a 23% downside. A more severe scenario, such as a failed product launch or a major reimbursement setback, could push the stock below $20, especially given its short trading history and lack of profitability. Investors should be prepared for drawdowns exceeding 40%, as evidenced by the past year's max drawdown of 48.66%.
FAQ
The most severe risk is the company's lack of profitability and negative cash flow, with a net margin of -66.35% and price-to-cash-flow of -46.02, which could force equity dilution if the path to breakeven is delayed. Second, the extreme valuation (14.12x sales) leaves the stock vulnerable to multiple compression if growth decelerates or if interest rates remain high. Third, competitive threats from alternative diagnostic modalities and potential reimbursement headwinds could slow adoption of Heartflow's products. Fourth, the stock's high volatility, evidenced by a 48.66% max drawdown and a 35.7% single-day earnings gap, means investors could face sharp losses in a short period.
Our 12-month forecast assigns a 25% probability to a bull case with a target range of $55-$65, driven by continued earnings beats and upward analyst revisions. The base case, with a 50% probability, targets $42-$48, assuming the company meets consensus estimates and the stock consolidates around the analyst average target of $44.78. The bear case, with a 25% probability, targets $30-$39, reflecting a growth deceleration or profitability delay. The most likely scenario is the base case, which assumes revenue of $515.9 million and forward EPS of $0.613 are achieved, leading to a modest pullback from current levels.
HTFL appears overvalued on both absolute and relative bases. The price-to-sales ratio of 14.12x and EV/Sales of 19.69x are well above the mid-to-high single-digit multiples typical of medtech and healthcare IT peers. The PEG ratio of 2.03 indicates the stock is not cheap even after adjusting for growth. While the 76.80% gross margin justifies a premium, the negative net margin of -66.35% means the valuation is a bet on future profitability rather than current fundamentals. The market is pricing in a rapid swing to the $0.613 forward EPS, and any disappointment could lead to significant multiple compression.
From a risk/reward perspective, HTFL is a Hold at current levels. The stock has surged 95% over six months and trades at a premium valuation of 14.12x sales, while the average analyst target of $44.78 implies 11.8% downside. The bull case rests on a durable growth inflection and a path to profitability, but the company is still unprofitable with a net margin of -66.35%. For aggressive investors with a long-term horizon, a pullback to the $42-$45 range could offer a more attractive entry point. However, the high volatility (max drawdown of 48.66%) and wide analyst target range ($39-$55) mean position sizing should be conservative.
HTFL is better suited for long-term investors who can tolerate high volatility and have a multi-year horizon. The company is in the early stages of commercializing a potentially disruptive technology, and the path to profitability may take several years. Short-term trading is risky due to event-driven moves like the 35.7% single-day earnings gap and the 48.66% max drawdown. A minimum holding period of 2-3 years is advisable to allow the growth story to play out and for the company to potentially achieve consistent GAAP profitability. The lack of a dividend and negative cash flow mean the investment return depends entirely on capital appreciation.
